CMPS
What one share of Compass Pathways holds
Pharmaceutical Preparations
We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments.
Compass Pathways’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.61 |
|---|---|
| Cash and investments | $3.19 |
| Debt | $0.37 |
| Book value | $0.62 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$2.62 | $0.02 | −$2.40 | — | −$4.06 |
| 2020 | — | −$3.55 | $0.01 | −$2.44 | — | — |
| 2021 | — | −$1.79 | $0.01 | −$1.70 | — | $6.77 |
| 2022 | — | −$2.16 | $0.01 | −$2.50 | — | $4.24 |
| 2023 | — | −$2.32 | $0.00 | −$1.91 | — | $3.64 |
| 2024 | — | −$2.30 | $0.00 | −$1.77 | — | $2.26 |
| 2025 | — | −$3.08 | — | −$1.68 | — | −$0.55 |